On a preliminary basis, T2 Biosystems (NASDAQ:TTOO) expects Q4 revenue of ~$3.0M, including ~$1.5M in product sales. It also closed 10 T2Dx contracts in the quarter.
$4.8M in new capital raised via its at-the-market stock sales agreement. $11.0M in cash and equivalents at year-end.
Shares up 7% premarket on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.